Last reviewed · How we verify
QVM149
QVM149 is a dual combination of a glucagon receptor antagonist and a glucagon-like peptide-1 (GLP-1) receptor agonist.
QVM149 is a dual combination of a glucagon receptor antagonist and a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Treatment of type 2 diabetes.
At a glance
| Generic name | QVM149 |
|---|---|
| Also known as | indacaterol acetate/glycopyrronium bromide/mometasone furoate, Mometasone/Indacaterol/Glycopyrronium, QVM149 150/50/160 μg once daily, delivered as powder in hard capsules via Concept1 inhaler |
| Sponsor | Dr. Grace Parraga |
| Drug class | GLP-1 receptor agonist and glucagon receptor antagonist |
| Target | GLP-1R, glucagon receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This dual combination aims to improve glycemic control and weight loss by inhibiting glucagon and enhancing GLP-1 activity. By doing so, QVM149 may help to reduce blood glucose levels and promote weight reduction in patients with type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- A 24-week rPMS Study in Real-world Setting for Enerzair
- Anti-inflammatory Effects Glycopyrronium (PHASE3)
- Investigating the Effects of QVM149 on MRI Ventilation Defects (PHASE3)
- Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium (PHASE3)
- Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma. (PHASE2)
- Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma (PHASE2)
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QVM149 CI brief — competitive landscape report
- QVM149 updates RSS · CI watch RSS
- Dr. Grace Parraga portfolio CI